Cowen Starts Radius Health (RDUS) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/11/2026
- Wall St set to open higher after August inflation report, oil price slide
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but on track for 8% weekly gain on supply concerns; US diesel hits record high
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- White House copper tariff plan stalls amid affordability concerns, sources say
- Micron's Taiwan workers to get rewards worth up to 68 months of pay
- Crude Inventory 0.4M Barrels Last Week - EIA
- Vertiv shares drop on acquisition skepticism, AI pullback
- S&P 500, Dow futures attempt recovery ahead of inflation report
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Canaccord Genuity Starts Radius Health (RDUS) at Buy
July 16, 2014 7:30 AM EDTCanaccord Genuity initiated coverage on Radius Health (NASDAQ: RDUS) with a Buy rating and a price target of $21.00.
For an analyst ratings summary and ratings history on Radius Health click here. For more ratings news on Radius Health click here.
Shares of Radius Health closed at $12.14 yesterday.
... MoreJefferies Starts Radius Health (RDUS) at Buy
July 16, 2014 7:23 AM EDTJefferies initiates coverage on Radius Health (NASDAQ: RDUS) with a Buy rating and a price target of $17.00.
Analyst Eun K. Yang, Ph.D. said, "Ahead of Ph3 data in 12/14, we view highly likely Ph3 success for abaloparatide-SC in osteoporosis (achieving primary endpoint of... More
Cantor Fitzgerald Starts Radius Health (RDUS) at Buy
July 16, 2014 6:52 AM EDTCantor Fitzgerald initiates coverage on Radius Health (NASDAQ: RDUS) with a Buy rating and a price target of $20.00.
Analyst Mara Goldstein said, " We like the simplicity of the company's value proposition: a late stage asset with near-term revenue potential, with the potential... More
